New journal looks at hot button issue

Share this article:
First Lady Michelle Obama's recent announcement of a campaign to end childhood obesity was not lost on medical publisher Mary Ann Liebert, Inc., which will roll out a new journal, Childhood Obesity, in June 2010.

The journal represents a re-branding of Liebert's Obesity and Weight Management, which will be folded into the new title. Vicki Cohn, executive VP and managing editor at Liebert, said the decision to focus the journal on childhood obesity was “not an advertising thing,” but reflects “the enormous problem” of childhood obesity.

“It's a hot subject,” said Cohn.

The re-branded, peer-reviewed Childhood Obesity will offer original articles, perspectives from opinion leaders, safety and efficacy treatment regimens and case reports, among other features, to physicians, nurses and other healthcare professionals, according to a company statement.  

Cohn said Liebert has “maintained steady advertising sales” across its journal portfolio, which includes flagship Genetic Engineering and Biotechnology News, ASSAY and Drug Development Technologies, and AIDS Research and Human Retroviruses, among others covering biotechnology, medicine, surgery, nursing and integrative medicine.

Liebert titles are primarily subscription-based, said Cohn, adding that the company's journals go out to 140 countries. For 2010, 15 Liebert titles will increase the number of issues published each year, according to the website.

“Mrs. Obama is right when she says that childhood obesity threatens the nation's economic health,” said Mary Ann Liebert, the company's namesake president and CEO, in a statement. “The costs of health care related to obesity-related conditions such as diabetes and heart disease are enormous. Healthy people are productive people. Weight management starts in childhood.”
Share this article:
close

Next Article in Features

Email Newsletters

More in Features

Antidote: On Cystic Fibrosis treatments

Antidote: On Cystic Fibrosis treatments

Recent treatments in CF, including the inhaled antibiotic Tobramycin, have increased lifespan well into adulthood.

The $3 generic and the $1,000 pill: pharma outsiders just don't get it

The $3 generic and the $1,000 pill: pharma ...

What do you call the people who treat medical breakthroughs as if they were bank heists? Malicious? Uninformed? Not with it?

Leadership Exchange Uncut : The Agency-Client Relationship

Leadership Exchange Uncut : The Agency-Client Relationship

Click the above link to access MM&M's first Leadership Exchange Uncut e-book, "The Agency-Client Relationship"